{"name":"Janux Therapeutics","slug":"janux","ticker":"JANX","exchange":"NASDAQ","domain":"januxrx.com","description":"Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study devel","hq":"La Jolla, CA","founded":0,"employees":"109","ceo":"David Hung","sector":"Oncology / Immuno-Oncology","stockPrice":14.71,"stockChange":-0.22,"stockChangePercent":-1.47,"marketCap":"$895M","metrics":{"revenue":10000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":125896000,"netIncome":-113625000,"cash":52334000,"dividendYield":0,"peRatio":-4.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Janux Therapeutics Announces FDA Clearance of IND for JX-594","summary":"Janux Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for JX-594, a novel oncolytic immunotherapy.","drugName":"JX-594","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Janux Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Janux Therapeutics reported its financial results for the third quarter of 2023, highlighting progress in its pipeline and financial position.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOYlJNNjJMdkdsekpoS3h2TDFIWWZZRGtZdnRGcXQ1V2ZjbjFOMERqWG1peTRWcUd0WGtILTBGWHpOWGhFLU0wejJDRlVVLVhBcTZxT1VSS0hOSW9JcVp2REJISld1YTktaHBZcmp0dHZ2ZXpPSkpqaV9mQWhIZkZ4NEVGYmZyY2FOZmlsbUdhZ2pjY0hNRGJyVTR5YmFET0o0NjFCWlpKTXZhcjIyWTltMVk1T01HdmJQYlE?oc=5","date":"2026-04-02","type":"deal","source":"TradingView","summary":"Janux Therapeutics Secures $35M Milestone Payment From BMY Deal - TradingView","headline":"Janux Therapeutics Secures $35M Milestone Payment From BMY Deal","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-28","type":"pipeline","source":"simplywall.st","summary":"Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st","headline":"Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQQzZkb2lheGQzMVVLZVQ0ZXdnV0FqZ1VacHRHZERjOXJYZE9QR05mMzFLS2dJR1lXRDdHWFV3cndkOGV6UGtSZGpJTW9ENkZwbjV0OG1XdGhMcjV5YXl1MExhUGRwTGtYcHNNeEZMYnNCdmQ1QXkwZWJXTlNBanBhdk9nbzhkVHY1U1YtVlhvX01yaTQzQWtWdlFRMkt5SWZZZTc4Wmx5eHFQZUhBejByQThSeWVXdy1JZXg4YlRJY1R6WWM?oc=5","date":"2026-02-25","type":"deal","source":"San Diego Business Journal","summary":"Janux T Cell Engagers Attract Bristol Myers Squibb Development Deal - San Diego Business Journal","headline":"Janux T Cell Engagers Attract Bristol Myers Squibb Development Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOaDJKblJ2Y3MycEM5LWt1cm5QWXBkSllland2eVZ5OUp6ZFdRdjVEWWJXakd5a0VlellzZlZYUmJvQXpYMy00XzE2aW8wOGRDSWlVcHp2LW5FdnhkYmI3S1JzWHNrNlBSNTNKZ1lSRHV5NUI3S0o1MFVibl90WWUtaXpJWGRTeWdxTVVMYTllZGZIOHJ0NllqWGhudmo4SmlpMDVSXzdlUFVPXzZ1QkwxdFAxXzdNRU0?oc=5","date":"2026-02-16","type":"pipeline","source":"24/7 Wall St.","summary":"Wall Street Thinks These 4 Biotech Stocks Will Double--At Least--This Year - 24/7 Wall St.","headline":"Wall Street Thinks These 4 Biotech Stocks Will Double--At Least--This Year - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNWkZJbTFkU0xpSzFyRzdLbnJVOXliSjlMdVNvTkxQcHZFdWtYb3NnQW5IajRGeVd6UVJzYTBLdkJMQlBKQURNSEtVYWttNXRHSGlXZnVnTXpxU09uTkhJUXRPa2FlWXgzcWZKdEdsV2ZjcHlqenRTUXNsWE8ydzlHR0llRkJvRnM2ZF9LbElDSjBoWEJtb2pIeUtEZkpLOVJuaVZGT3lRUWlIejBISWRYU0dnTFE4QnBVZXhhSUFQQ3A2RS1qT2tfMmxTQQ?oc=5","date":"2026-01-26","type":"pipeline","source":"Business Wire","summary":"Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire","headline":"Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOaGx5TUVKTWY0YXIwWHFHX0hUam00aHhJZmpzN3Q0b3EtUkFHcFlpX0xBVGxuYkdlV2RBeEtKMUxoUHBwLUhzdm9wbERqWlhpS3BNVlVMd1ozcWk3WjRmY3B3U3BHb1VrQ1VkN0JIUFhrWGZET3Z1RU9XanZ3Ym1TZEo1dWdDS0hrT0lLaUI3OFFDMmVPT3ZrdFB3?oc=5","date":"2026-01-23","type":"deal","source":"The Pharma Letter","summary":"Janux Therapeutics rises on license deal with BMS - The Pharma Letter","headline":"Janux Therapeutics rises on license deal with BMS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNckl2S0RUTEJvV2VpU3I4clptMFdyalItY1g3MEh4emhmeUNQd1M1ODk1Ull3VnFVWU5ON3dFQ09Ta1RKbndVb1JtRXBPX2RlalZqQkN2R2pvWG9kME9HQkNLWGI5MnQ3SWZyQ05BTDdqTWpqOXlMYkJMS1U3SXNjOTd1ZGdtaTlMMThyMEVUVjhyZlpLSTdkUUFZRWFyemlCcTBfa0NXdDJHZi1ibm5CRThfZTNkblE4Mkt3MEotWHFYRURjQVNJX1I5WWxPRGZoSndxQm1wNzEyMTM0WFVBbEJaS2M?oc=5","date":"2026-01-22","type":"deal","source":"Reuters","summary":"Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters","headline":"Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbmFKbGRKaG5UbXJ0eTBRZE93aUItUFJZNXJSNGZQUXFtZThEM3R4NHRZQTVWZUxrbzY5ZGU0OWRzY0JhUnEwcE5QLUlWX0lkQzdKSDRxdUJvSU1YRHNUS3F4UDNPWHVxU0lQUnZha09Ud1pCVnVyMUliLUZzUVlKNnFKSXMwNTl4Q20yOWdQdkpQSGJ0ZG8xV2ZqXzUxQXplUDRNZ3JtVWZFUQ?oc=5","date":"2026-01-22","type":"pipeline","source":"MedCity News","summary":"BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy - MedCity News","headline":"BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy","sentiment":"neutral"},{"date":"2026-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPZXp6WksxU2J3VVkyNGMyT1ZlMXhDTko4YVFsSjYxcDJ2SVV3WFNEakc3Q21nZFhSNmw3VnhfNmpWSDJmNkRPQmUyd2VCcGdIMXFsRnpYN3hrWmhuZnljYzUwUWVDeDRUeDNhQ0lvYzdEYXRjVkdHZk1Ka1ZHUmxqNnpCdW9yZFZJQXRKU05aLTNaX2RyLWVMUQ?oc=5","date":"2025-12-02","type":"trial","source":"Barron's","summary":"Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%. - Barron's","headline":"Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%. - Barron's","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOUE5FU3ZVdUhmYWw5dGFVb2Q3VDlZRHo3Z1MwNUs4QnBvbXM1cHZ2eVlYYXM5c0pYNnVEcmJ3cllRRXFzUFlyNmlSVk5IblJIWE5oMHdudmZPM004dFlSMUlyRGJQMVdPeTJKcUhia29GZ2VaMlhYVXp1T0h1MWRka0RubGRFSkRBek9JNERySUxXcjFhRWMzMElMX1ZwbUNBV1NWSldqbWk3WWVWM0x1RnZVYS1JTVNqOUQ1VFkzZnd1djVZN3ktQjdMUQ?oc=5","date":"2025-12-02","type":"trial","source":"Seeking Alpha","summary":"Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade) - Seeking Alpha","headline":"Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPQ2h0Z3QtdnJSZXRUeDNrTDJveklNR19pdllGQk9IVEZvN3BqTWRtVnd4bjhyQnVFMkhnQmFqWENkejltWXdOMXhlc3FkX0JzTkRyM0ZOQ0FldHNvd2tpWTJ5ek42MkJSSFJvUjBPaVhYM0syNURpb3dLZl9CckxjWENhWUdsYmtXU2k2ZkFDUVE?oc=5","date":"2025-08-17","type":"deal","source":"Yahoo Finance","summary":"Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - Yahoo Finance","headline":"Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE84bFB5ZklSR2ZoTkRGVklIMmlSbjI4ZVdNc0prMUp4aDBkY0dGU2tsVEdadDRuclhELXRXWTN4WDBtNUlJSzUtLU1NaFg4cEhJcjBj?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"JANX Stock Price, News & Analysis - Stock Titan","headline":"JANX Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Immuno-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":125896000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-113625000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":52334000,"cashHistory":[],"totalAssets":1001565000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":109,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14.71,"previousClose":14.93,"fiftyTwoWeekHigh":35.34,"fiftyTwoWeekLow":12.12,"fiftyTwoWeekRange":"12.12 - 35.34","fiftyDayAverage":13.74,"twoHundredDayAverage":20.65,"beta":2.81,"enterpriseValue":-36211376,"forwardPE":-4.2,"priceToBook":0.93,"priceToSales":89.48,"enterpriseToRevenue":-3.62,"enterpriseToEbitda":0.23,"pegRatio":0,"ebitda":-155638000,"ebitdaMargin":0,"freeCashflow":-51267876,"operatingCashflow":-82235000,"totalDebt":22139000,"debtToEquity":2.3,"currentRatio":39.04,"returnOnAssets":-9.6,"returnOnEquity":-11.5,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":16,"targetMeanPrice":54,"targetHighPrice":100,"targetLowPrice":25,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6.9,"institutionHeldPercent":105,"sharesOutstanding":60831656,"floatShares":41680634,"sharesShort":10020131,"shortRatio":11.5,"shortPercentOfFloat":16.5,"epsTrailing":-1.83,"epsForward":-3.49,"revenuePerShare":0.16,"bookValue":15.85,"officers":[{"age":65,"name":"Dr. David Alan Campbell Ph.D.","title":"President, CEO & Director"},{"age":38,"name":"Dr. Thomas  Diraimondo Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Matt  Whitmire","title":"Vice President of Finance"},{"age":35,"name":"Ms. Maria  Dobek","title":"Vice President of Accounting"},{"age":55,"name":"Mr. Charles M. Winter","title":"Chief Technical Officer"},{"age":null,"name":"Mr. James  Pennington","title":"General Counsel & Corporate Secretary"},{"age":null,"name":"Ms. Janeen  Doyle","title":"Chief Corporate & Business Development Officer"},{"age":null,"name":"Dr. William Y. Go M.D., Ph.D.","title":"Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.januxrx.com","phone":"858 751 4493"}}